Skip to content

Evommune EVMN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$2M
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$1.22M+234%
Hims & Hers Health logo
Hims & Hers HealthHIMS
$5.01M+27.5%

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M
Total equity-$4.5M-3,048%
Total assets$7.2M

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$848.59M+39.5%
Enterprise value$849.52M
P/S127.3×

Profitability

See full
Gross margin53.7%
Operating margin-30.7%
Net margin-90.1%

Returns & leverage

See full
Return on equity275.7%
Debt / equity1.4×
Current ratio1.2×

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evommune 's stock issuance proceeds?
Evommune (EVMN) reported stock issuance proceeds of $123.29K in Q1 2026.
How has Evommune 's stock issuance proceeds changed year-over-year?
Evommune 's stock issuance proceeds decreased by 51.3% year-over-year, from $252.9K to $123.29K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.